Primary Sclerosing Cholangitis: Is any treatment worthwhile?

Current Gastroenterology Reports

Volumn 14, Issue 1, 2012, Pages 17-24

  Barnabas, Ashley ^a   Chapman, Roger W ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Antibiotics; Autoimmune hepatitis PSC overlap; Hepatic osteodystrophy; Liver transplantation; Nuclear hormone receptor antagonists; Primary sclerosing cholangitis; PSC with autoimmune features; PSC IBD; Ursodeoxycholic acid

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BEZAFIBRATE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID DERIVATIVE; ETANERCEPT; FARNESOID X RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G4; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METRONIDAZOLE; MINOCYCLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; PREDNISOLONE; RIFAMPICIN; RIFAXIMIN; URSODEOXYCHOLIC ACID; VANCOMYCIN; VITAMIN D; VITAMIN D RECEPTOR; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOIMMUNE HEPATITIS; BALLOON DILATATION; BILE DUCT CANCER; BILE DUCT OBSTRUCTION; BILIARY TRACT SURGERY; CELL PROTECTION; DRUG FATALITY; DRUG MEGADOSE; DRUG TARGETING; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC SURGERY; HUMAN; IMMUNOMODULATION; LIVER NECROSIS; LIVER TRANSPLANTATION; METABOLIC BONE DISEASE; MULTICENTER STUDY (TOPIC); NONALCOHOLIC FATTY LIVER; NONHUMAN; OSTEOPENIA; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT; TREATMENT OUTCOME;

CHOLANGITIS, SCLEROSING; HUMANS; LIVER TRANSPLANTATION; URSODEOXYCHOLIC ACID;

EID: 84857635070     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-011-0230-8     Document Type: Article

References (55)

1. JR Maggs RW Chapman 2008 An update on primary sclerosing cholangitis Curr Opin Gastroenterol. 24 3 377 383 18408468 10.1097/MOG.0b013e3282f9e239 (Pubitemid 351535898)
2. EV Loftus Jr GC Harewood CG Loftus, et al. 2005 PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis Gut 54 1 91 96 15591511 10.1136/gut.2004.046615 (Pubitemid 40007225)
3. ST Chari 2007 Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic's HISORt criteria J Gastroenterol. 42 Suppl 18 39 41 17520222 10.1007/s00535-007-2046-8 (Pubitemid 46863936)
4. J Lee A Belanger JT Doucette, et al. 2007 Transplantation trends in primary biliary cirrhosis Clin Gastroenterol Hepatol. 5 11 1313 1315 17900996 10.1016/j.cgh.2007.07.015 (Pubitemid 350019058)
5. PP Stanich E Bjornsson KD Lindor, et al. 2011 Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis Dig Liver Dis. 43 4 309 313 21251891 10.1016/j.dld.2010.12.008 1:CAS:528:DC%2BC3MXjs1Cmur4%3D
6. G Paumgartner U Beuers 2002 Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited Hepatology. 36 3 525 531 12198643 10.1053/jhep.2002.36088 1:CAS:528:DC%2BD38XnvVSkt74%3D (Pubitemid 34977162)
7. KD Lindor 1997 Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group N Engl J Med 336 10 691 695 9041099 10.1056/NEJM199703063361003 1:CAS:528:DyaK2sXitValtbw%3D (Pubitemid 27102683)
8. SA Mitchell DS Bansi RW Chapman, et al. 2001 A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis Gastroenterology 121 4 900 907 11606503 10.1053/gast.2001.27965 1:CAS:528:DC%2BD3MXnvVynur4%3D (Pubitemid 32959399)
9. R Olsson KM Boberg OS de Muckadell, et al. 2005 High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study Gastroenterology 129 5 1464 1472 16285948 10.1053/j.gastro. 2005.08.017 1:CAS:528:DC%2BD2MXht12gsr7O (Pubitemid 41597389)
10. KD Lindor KV Kowdley VA Luketic, et al. 2009 High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis Hepatology 50 3 808 814 19585548 10.1002/hep.23082 1:CAS:528:DC%2BD1MXhtFKntL%2FJ This landmark trial suggested that higher dose UDCA is potentially harmful in PSC.
11. SN Cullen C Rust RW Chapman, et al. 2008 High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective J Hepatol. 48 5 792 800 18314215 10.1016/j.jhep.2007.12.023 1:CAS:528: DC%2BD1cXktVGrurw%3D
12. DM Harnois P Angulo KD Lindor, et al. 2001 High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis Am J Gastroenterol. 96 5 1558 1562 11374699 10.1111/j.1572-0241.2001.03777.x 1:STN:280:DC%2BD3M3ptF2jsA%3D%3D (Pubitemid 32455090)
13. P Fickert G Zollner A Fuchsbichler, et al. 2002 Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles Gastroenterology 123 4 1238 1251 12360485 10.1053/gast.2002.35948 1:CAS:528:DC%2BD38Xotl2ns7Y%3D
14. A Benedetti D Alvaro C Bassotti, et al. 1997 Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver Hepatology 26 1 9 21 9214446 10.1002/hep.510260102 1:CAS:528:DyaK2sXkslagt7k%3D (Pubitemid 27280301)
15. JD Martinez ED Stratagoules JM LaRue, et al. 1998 Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation Nutr Cancer. 31 2 111 118 9770722 10.1080/01635589809514689 1:CAS:528:DyaK1cXmtlOrsbs%3D (Pubitemid 28428071)
16. BY Tung MJ Emond RC Haggitt, et al. 2001 Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis Ann Intern Med. 134 2 89 95 11177311 1:STN:280:DC%2BD3M7ktVSntw%3D%3D (Pubitemid 32096335)
17. JM Wolf LA Rybicki BA Lashner 2005 The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis Aliment Pharmacol Ther. 22 9 783 788 16225486 10.1111/j.1365-2036.2005.02650.x 1:CAS:528:DC%2BD2MXht1yis77J (Pubitemid 41564357)
18. DS Pardi EV Loftus Jr KD Lindor, et al. 2003 Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis Gastroenterology 124 4 889 893 12671884 10.1053/gast.2003.50156 1:CAS:528:DC%2BD3sXjsFOjurY%3D (Pubitemid 36389790)
19. G Rudolph P Kloeters-Plachky D Rost A Stiehl 2007 The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid Eur J Gastroenterol Hepatol. 19 6 487 491 17489059 10.1097/MEG.0b013e3281108068 1:CAS:528:DC%2BD2sXltVSmsb4%3D (Pubitemid 46725755)
20. B Brandsaeter H Isoniemi U Broome, et al. 2004 Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy J Hepatol. 40 5 815 822 15094230 10.1016/j.jhep.2004.01.002 1:STN:280:DC%2BD2c3osl2mug%3D%3D (Pubitemid 38507363)
21. Eaton JE, Silveira MG, Pardi DS, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol. May 10 2011.
22. SS Glaser G Alpini 2009 Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis Hepatology 49 6 1795 1797 19475683 10.1002/hep.22969 1:CAS:528:DC%2BD1MXotVCmtLw%3D
23. E Halilbasic R Fiorotto P Fickert, et al. 2009 Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice Hepatology 49 6 1972 1981 19475687 10.1002/hep.22891 1:CAS:528:DC%2BD1MXotVCmtbk%3D
24. AP Day MD Feher R Chopra PD Mayne 1993 The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities Metabolism 42 7 839 842 8102192 10.1016/0026-0495(93)90056-T 1:STN:280:DyaK3szkslKhtA%3D%3D (Pubitemid 23207110)
25. MP Epstein MM Kaplan 2004 A pilot study of etanercept in the treatment of primary sclerosing cholangitis Dig Dis Sci. 49 1 1 4 14992426 10.1023/B:DDAS.0000011827.87103.2e 1:CAS:528:DC%2BD2cXislentw%3D%3D (Pubitemid 38183736)
26. DW Hommes W Erkelens C Ponsioen, et al. 2008 A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis J Clin Gastroenterol 42 5 522 526 18344886 10.1097/MCG. 0b013e3181662426 1:CAS:528:DC%2BD1cXltVWnu7k%3D (Pubitemid 351572276)
27. MG Silveira NJ Torok AA Gossard, et al. 2009 Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study Am J Gastroenterol. 104 1 83 88 19098854 10.1038/ajg.2008.14 1:CAS:528: DC%2BD1MXht1Sgtw%3D%3D
28. M Farkkila AL Karvonen H Nurmi, et al. 2004 Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial Hepatology 40 6 1379 1386 15565569 10.1002/hep.20457 (Pubitemid 39657012)
29. YK Davies KM Cox KL Cox, et al. 2008 Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic J Pediatr Gastroenterol Nutr. 47 1 61 67 18607270 10.1097/MPG.0b013e31816fee95 1:CAS:528:DC%2BD1cXot1ylsLw%3D
30. KM Boberg RW Chapman E Schrumpf, et al. 2011 Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue J Hepatol. 54 2 374 385 21067838 10.1016/j.jhep.2010.09.002 Clinically a very useful consensus statement on the management of cholestatic liver diseases with overlapping features.
31. A Floreani ER Rizzotto F Ferrara, et al. 2005 Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome Am J Gastroenterol. 100 7 1516 1522 15984974 10.1111/j.1572-0241.2005.41841.x (Pubitemid 41032356)
32. KM Boberg O Fausa T Haaland, et al. 1996 Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis Hepatology 23 6 1369 1376 8675153 10.1002/hep.510230612 1:STN:280:DyaK283ktlWmtw%3D%3D (Pubitemid 26181218)
33. T Al-Chalabi BC Portmann MA Heneghan, et al. 2008 Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival Aliment Pharmacol Ther. 28 2 209 220 18433467 10.1111/j.1365-2036.2008. 03722.x 1:CAS:528:DC%2BD1cXps1Gmt7w%3D Long-term follow up of groups of patients with both PSC and PBC with autoimmune features, and a comparison with patients with autoimmune hepatitis. (Pubitemid 351861961)
34. S Luth S Kanzler C Frenzel, et al. 2009 Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome J Clin Gastroenterol. 43 1 75 80 18769363 10.1097/MCG.0b013e318157c614
35. HR van Buuren HJE van Hoogstraten FP Vleggaar, et al. 2000 High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis J Hepatol. 33 4 543 548 11059858 10.1034/j.1600-0641.2000.033004543. x
36. R Olsson H Glaumann S Almer, et al. 2009 High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis Eur J Intern Med. 20 2 190 196 19327611 10.1016/j.ejim.2008.06.004
37. R Chapman J Fevery A Kalloo, et al. 2010 Diagnosis and management of primary sclerosing cholangitis Hepatology 51 2 660 678 20101749 10.1002/hep.23294 1:CAS:528:DC%2BC3cXisVGnsrg%3D
38. DN Gotthardt G Rudolph A Stiehl, et al. 2010 Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment Gastrointest Endosc. 71 3 527 534 20189511 10.1016/j.gie.2009.10.041 171 patients with a dominant biliary stricure were followed up for up to 21 years. A total of 500 balloon dilatations were done and 52% survived free of transplant at 10 years.
39. AWM van Milligen de Wit J van Bracht EAJ Rauws, et al. 1996 Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis Gastrointest Endosc. 44 3 293 299 8885349 10.1016/S0016-5107(96)70167-0 (Pubitemid 26318331)
40. CY Ponsioen K Lam GN Tytgat, et al. 1999 Four years experience with short term stenting in primary sclerosing cholangitis Am J Gastroenterol. 94 9 2403 2407 10483999 10.1111/j.1572-0241.1999.01364.x 1:STN:280:DyaK1MvhtFyjsg%3D%3D (Pubitemid 29420664)
41. AR Baluyut S Sherman N Chalasani, et al. 2001 Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis Gastrointest Endosc. 53 3 308 312 11231388 1:STN:280:DC%2BD3Mzgt1Whug%3D%3D (Pubitemid 32207314)
42. M Gluck N Cantone RA Kozarek, et al. 2008 A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis J Clin Gastroenterol. 42 9 1032 1039 18580600 10.1097/MCG.0b013e3181646713
43. PR Tarnasky 1999 Primary sclerosing cholangitis: resect, dilate, or transplant? Gastrointest Endosc. 49 3 Pt 1 406 408 10206787 1:STN:280: DyaK1M3hvFWlsw%3D%3D
44. M Aljiffry PD Renfrew M Molinari, et al. 2011 Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis HPB (Oxford). 13 2 79 90 10.1111/j.1477-2574.2010.00268.x
45. S Tamura Y Sugawara N Kokudo, et al. 2009 The urgent need for evaluating recurrent primary sclerosing cholangitis in living donor liver transplantation Liver Transpl. 15 10 1383 1384 19790228 10.1002/lt.21794 author reply 1385
46. IW Graziadei 2011 Live donor liver transplantation for primary sclerosing cholangitis: is disease recurrence increased? Curr Opin Gastroenterol. 27 3 301 305 21248637 10.1097/MOG.0b013e3283437a8c
47. H Egawa Y Ueda T Ichida, et al. 2011 Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation in Japanese registry Am J Transplant. 11 3 518 527 21219581 10.1111/j.1600-6143. 2010.03402.x 1:STN:280:DC%2BC3M3pvF2kug%3D%3D
48. E Alabraba P Nightingale B Gunson, et al. 2009 A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts Liver Transpl. 15 3 330 340 19243003 10.1002/lt.21679
49. M Rahman P Desmond N Mortensen RW Chapman 2011 The clinical impact of primary sclerosing cholangitis in patients with an ileal pouch-anal anastomosis for ulcerative colitis Int J Colorectal Dis. 26 5 553 559 21279368 10.1007/s00384-011-1140-9
50. P Angulo GA Grandison DG Fong, et al. 2011 Bone disease in patients with primary sclerosing cholangitis Gastroenterology. 140 1 180 188 20955707 10.1053/j.gastro.2010.10.014
51. P Angulo TM Therneau A Jorgensen, et al. 1998 Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression J Hepatol. 29 5 729 735 9833910 10.1016/S0168-8278(98)80253-5 1:STN:280:DyaK1M%2FkvFKmtA%3D%3D (Pubitemid 28505929)
52. MM Guichelaar R Kendall M Malinchoc JE Hay 2006 Bone mineral density before and after OLT: long-term follow-up and predictive factors Liver Transpl. 12 9 1390 1402 16933236 10.1002/lt.20874 (Pubitemid 44405129)
53. S Khurana P Singh 2006 Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials Liver Int. 26 8 943 948 16953834 10.1111/j.1478-3231.2006.01326.x 1:CAS:528:DC%2BD28XhtF2qsbzK (Pubitemid 44323412)
54. Y Liu J Binz MJ Numerick, et al. 2003 Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis J Clin Invest. 112 11 1678 1687 14623915 1:CAS:528:DC%2BD3sXpslens70%3D (Pubitemid 38063725)
55. U Beuers U Spengler W Kruis, et al. 1992 Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial Hepatology. 16 3 707 714 1505913 10.1002/hep.1840160315 1:STN:280: DyaK38zntF2ntQ%3D%3D